Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib + bevacizumab in advanced or metastatic neuroendocrine tumors
2008-000225-19Phase 2Active
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and bevacizumab in apudoma (NET), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Progression-free rate at 6 months. Started Apr 2008; status: active.
02
Drugs
sorafenibbevacizumab
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2008-000225-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000225-19.